|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
84,000,000 |
Market
Cap: |
37.78(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.28 - $0.965 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Dare Bioscience is a biopharmaceutical company committed to developing products for women's health. Co.'s product, XACIATO, is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. Co.'s programs target unmet needs in women's health in the areas of contraception, fertility and vaginal and sexual health. Co.'s product candidates in clinical development include: Ovaprene®, a hormone-free, monthly contraceptive; and Sildenafil Cream, 3.6%, a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Walt David R |
Director |
|
2016-01-11 |
4 |
AB |
$2.86 |
$12,471 |
D/D |
4,355 |
53,947 |
|
- |
|
Walt David R |
Director |
|
2016-01-08 |
4 |
AB |
$2.87 |
$12,937 |
D/D |
4,500 |
49,592 |
|
- |
|
Walt David R |
Director |
|
2016-01-07 |
4 |
AB |
$2.87 |
$12,346 |
D/D |
4,300 |
45,092 |
|
- |
|
Walt David R |
Director |
|
2016-01-06 |
4 |
AB |
$3.03 |
$13,639 |
D/D |
4,500 |
40,792 |
|
- |
|
Oneill James E |
Principal Accounting Officer |
|
2015-12-31 |
4 |
A |
$2.38 |
$2,613 |
D/D |
1,098 |
2,098 |
|
- |
|
Guiffre Christopherd T |
Chief Executive Officer |
|
2015-12-31 |
4 |
A |
$2.38 |
$6,562 |
D/D |
2,757 |
2,757 |
|
- |
|
Walt David R |
Director |
|
2015-12-03 |
4 |
B |
$3.75 |
$37,488 |
D/D |
10,000 |
27,491 |
2.39 |
- |
|
Walt David R |
Director |
|
2015-11-30 |
4 |
B |
$3.25 |
$17,460 |
D/D |
5,374 |
17,491 |
2.39 |
- |
|
Walt David R |
Director |
|
2015-11-27 |
4 |
B |
$3.28 |
$21,964 |
D/D |
6,700 |
12,117 |
2.39 |
- |
|
Walt David R |
Director |
|
2015-11-25 |
4 |
B |
$3.37 |
$18,233 |
D/D |
5,417 |
5,417 |
2.39 |
- |
|
Oneill James E |
Principal Accounting OfficerOf |
|
2015-06-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
- |
|
Cvf Llc |
10% Owner |
|
2015-04-07 |
4 |
B |
$6.00 |
$1,999,998 |
D/D |
333,333 |
2,592,577 |
2.45 |
- |
|
62 Records found
|
|
Page 3 of 3 |
|
|